B. Riley Research Analysts Raise Earnings Estimates for XFOR

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) – B. Riley increased their FY2024 EPS estimates for X4 Pharmaceuticals in a research note issued to investors on Monday, November 18th. B. Riley analyst K. Patel now expects that the company will post earnings of ($0.17) per share for the year, up from their previous forecast of ($0.68). The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.50) per share. B. Riley also issued estimates for X4 Pharmaceuticals’ FY2025 earnings at ($0.29) EPS, FY2026 earnings at ($0.24) EPS, FY2027 earnings at ($0.21) EPS and FY2028 earnings at ($0.16) EPS.

Several other analysts have also weighed in on the stock. HC Wainwright lowered their target price on shares of X4 Pharmaceuticals from $5.00 to $1.50 and set a “buy” rating for the company in a research note on Thursday, November 14th. Stifel Nicolaus lowered their price target on shares of X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating for the company in a research report on Thursday, November 14th.

X4 Pharmaceuticals Stock Performance

XFOR stock opened at $0.37 on Wednesday. The company has a current ratio of 4.89, a quick ratio of 4.80 and a debt-to-equity ratio of 1.26. X4 Pharmaceuticals has a 1-year low of $0.26 and a 1-year high of $1.60. The firm has a fifty day moving average price of $0.56 and a two-hundred day moving average price of $0.73.

Hedge Funds Weigh In On X4 Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD grew its holdings in X4 Pharmaceuticals by 46.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 39,307 shares of the company’s stock valued at $55,000 after purchasing an additional 12,514 shares during the last quarter. Rhumbline Advisers boosted its position in shares of X4 Pharmaceuticals by 14.6% in the second quarter. Rhumbline Advisers now owns 187,246 shares of the company’s stock valued at $109,000 after acquiring an additional 23,831 shares during the period. Verition Fund Management LLC bought a new stake in shares of X4 Pharmaceuticals in the third quarter valued at approximately $30,000. XTX Topco Ltd boosted its position in shares of X4 Pharmaceuticals by 41.7% in the third quarter. XTX Topco Ltd now owns 157,642 shares of the company’s stock valued at $106,000 after acquiring an additional 46,397 shares during the period. Finally, SG Americas Securities LLC bought a new stake in shares of X4 Pharmaceuticals in the third quarter valued at approximately $37,000. Institutional investors and hedge funds own 72.03% of the company’s stock.

Insider Buying and Selling at X4 Pharmaceuticals

In related news, COO Mary Dibiase sold 67,695 shares of the stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $0.57, for a total value of $38,586.15. Following the transaction, the chief operating officer now owns 452,060 shares in the company, valued at approximately $257,674.20. This represents a 13.02 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Paula Ragan sold 239,436 shares of the stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $0.55, for a total value of $131,689.80. Following the completion of the transaction, the chief executive officer now owns 1,057,713 shares in the company, valued at $581,742.15. This represents a 18.46 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 580,800 shares of company stock valued at $321,447. 1.62% of the stock is currently owned by corporate insiders.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.